-+ 0.00%
-+ 0.00%
-+ 0.00%
SyntekaBio Says Kymera Terminates Drug Discovery Contract
Share
Listen to the news
SyntekaBio Says Kymera Terminates Drug Discovery Contract
  • SyntekaBio’s drug discovery contract with Kymera Therapeutics was terminated, involving KRW 256.89 million, equivalent to 208.17% of 2023 revenue.
  • Kymera halted the project following a review of research results and progress.
  • Termination notice was received November 16, 2026; termination takes effect November 30, ahead of the scheduled December 31 expiry.
  • The original USD 230,000 contract included USD 150,000 in milestone payments and up to USD 80,000 for compound purchases and delivery.
  • The termination amount excludes USD 53,078.75 in reimbursed expenses, which were not recognized as revenue.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SyntekaBio Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261116902591), on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending